Berber, IlhamiErkurt, Mehmet AliKuku, IrfanMaya, EminBag, Harika GozukaraNizam, IlknurKoroglu, Mustafa2024-08-042024-08-0420161473-0502https://doi.org/10.1016/j.transci.2016.01.012https://hdl.handle.net/11616/97138This study aimed to evaluate the efficiency of DHAP regimen plus filgrastim for mobilization of stem cells in patients with recurrent and/or refractory lymphoma. Thirty-four patients who took DHAP as salvage therapy prior to autologous stem cell transplantation were included. After chemotherapies, 2 cycles of DHAP plus filgrastim were administered to the patients. Stem cells from 32 patients (94%) were collected on median 11th day (8-12), and the median collected CD34(+) cell dose was 9.7 x 10(6)/kg (range 3.8-41.6). DHAP plus filgrastim was found to be an effective chemotherapy regimen in mobilizing CD34(+) stem cells into the peripheral. (c) 2016 Elsevier Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccessDHAP plus filgrastimStem cell mobilizationLymphomaArticle54148522680968410.1016/j.transci.2016.01.0122-s2.0-84955315160Q3WOS:000374614700009Q4